Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. (2nd January 2022)

• Record Type: Journal Article
• Authors: Solana-Altabella, Antonio; Ballesta-López, Octavio; Megías-Vericat, Juan Eduardo; Martínez-Cuadrón, David; Montesinos, Pau
• Is Part Of: Expert opinion on emerging drugs. Volume 27:Number 1(2022)
• Page Start: 1
• Page End: 18
• Publication Date: 2022-01-02
• Subjects: FLT3 inhibitors -- acute myeloid leukemia -- midostaurin -- gilteritinib -- quizartinib -- crenolanib -- venetoclax -- hypomethylating agents; Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1080/14728214.2021.2009800
• Languages: English
• ISSNs: 1472-8214

Abstract

ABSTRACT: Introduction: The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in one-third of patients with Acute Myeloid Leukemia (AML). Midostaurin, quizartinib, and gilteritinib have been approved in the last years for the treatment of AML, and more Tyrosine Kinase Inhibitors (TKIs) targeting FLT3 are being developed such as crenolanib. Areas covered: In this systematic review, we will analyze the available clinical data on FLT3 inhibitors in development and describe the potential role that these FLT3-TKIs may play in the future management of FLT3-mutated (FLT3mut) AML. Expert opinion: Although several aspects may challenge the use of FLT3 inhibitors in AML (resistance mechanisms, on- and off-target toxicities or drug-drug interactions), these drugs are generally well tolerated, particularly if we compare their safety profile with classical chemotherapy agents or even with newer immunotherapies, thus enabling their use in fit and unfit AML patients, alone or combined. As AML is a polyclonal disease and FLT3 mutations are a late leukemogenic event, combinations of these FLT3 inhibitors with other antileukemic agents (like venetoclax or hypomethylating agents) seem a necessary research pathway.